Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testingErin G. Sutcliffe, Kathleen S. Hruska, Megan L. Marshall et al.|Cancer Genetics|2020Cited by 39
Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel TestingJessica L. Mester, Kathleen S. Hruska, Sarah A. Jackson et al.|Journal of Molecular Diagnostics|2019Cited by 23